Literature DB >> 24463572

Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.

Steven M Lewis1, Xiufeng Wu2, Anna Pustilnik3, Arlene Sereno3, Flora Huang3, Heather L Rick4, Gurkan Guntas4, Andrew Leaver-Fay4, Eric M Smith3, Carolyn Ho3, Christophe Hansen-Estruch3, Aaron K Chamberlain3, Stephanie M Truhlar3, Elaine M Conner4, Shane Atwell3, Brian Kuhlman5, Stephen J Demarest3.   

Abstract

Robust generation of IgG bispecific antibodies has been a long-standing challenge. Existing methods require extensive engineering of each individual antibody, discovery of common light chains, or complex and laborious biochemical processing. Here we combine computational and rational design approaches with experimental structural validation to generate antibody heavy and light chains with orthogonal Fab interfaces. Parental monoclonal antibodies incorporating these interfaces, when simultaneously co-expressed, assemble into bispecific IgG with improved heavy chain-light chain pairing. Bispecific IgGs generated with this approach exhibit pharmacokinetic and other desirable properties of native IgG, but bind target antigens monovalently. As such, these bispecific reagents may be useful in many biotechnological applications.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24463572     DOI: 10.1038/nbt.2797

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  44 in total

1.  Automated design of specificity in molecular recognition.

Authors:  James J Havranek; Pehr B Harbury
Journal:  Nat Struct Biol       Date:  2003-01

2.  Protein-protein docking with simultaneous optimization of rigid-body displacement and side-chain conformations.

Authors:  Jeffrey J Gray; Stewart Moughon; Chu Wang; Ora Schueler-Furman; Brian Kuhlman; Carol A Rohl; David Baker
Journal:  J Mol Biol       Date:  2003-08-01       Impact factor: 5.469

3.  'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.

Authors:  J B Ridgway; L G Presta; P Carter
Journal:  Protein Eng       Date:  1996-07

4.  An efficient route to human bispecific IgG.

Authors:  A M Merchant; Z Zhu; J Q Yuan; A Goddard; C W Adams; L G Presta; P Carter
Journal:  Nat Biotechnol       Date:  1998-07       Impact factor: 54.908

Review 5.  Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.

Authors:  Christian Klein; Claudio Sustmann; Markus Thomas; Kay Stubenrauch; Rebecca Croasdale; Jürgen Schanzer; Ulrich Brinkmann; Hubert Kettenberger; Jörg T Regula; Wolfgang Schaefer
Journal:  MAbs       Date:  2012-08-27       Impact factor: 5.857

Review 6.  Targeting T cells with bispecific antibodies for cancer therapy.

Authors:  Lawrence G Lum; Archana Thakur
Journal:  BioDrugs       Date:  2011-12-01       Impact factor: 5.807

7.  VH/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Yasufumi Kikuchi; Maki Yoshida; Megumi Tanaka; Akiko Koga; Yasuo Sekimori; Tetsuro Orita; Yoshinori Aso; Kunihiro Hattori; Masayuki Tsuchiya
Journal:  Protein Eng Des Sel       Date:  2010-06-24       Impact factor: 1.650

8.  The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

Authors:  Rita Nahta; Mien-Chie Hung; Francisco J Esteva
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

9.  Characterization of inhibitory anti-insulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo.

Authors:  Adam Doern; Xianjun Cao; Arlene Sereno; Christopher L Reyes; Angelina Altshuler; Flora Huang; Cathy Hession; Albert Flavier; Michael Favis; Hon Tran; Eric Ailor; Melissa Levesque; Tracey Murphy; Lisa Berquist; Susan Tamraz; Tracey Snipas; Ellen Garber; William S Shestowsky; Rachel Rennard; Christilyn P Graff; Xiufeng Wu; William Snyder; Lindsay Cole; David Gregson; Michael Shields; Steffan N Ho; Mitchell E Reff; Scott M Glaser; Jianying Dong; Stephen J Demarest; Kandasamy Hariharan
Journal:  J Biol Chem       Date:  2009-02-11       Impact factor: 5.157

10.  Phaser crystallographic software.

Authors:  Airlie J McCoy; Ralf W Grosse-Kunstleve; Paul D Adams; Martyn D Winn; Laurent C Storoni; Randy J Read
Journal:  J Appl Crystallogr       Date:  2007-07-13       Impact factor: 3.304

View more
  96 in total

1.  Heavy and light chain pairing of bivalent quadroma and knobs-into-holes antibodies analyzed by UHR-ESI-QTOF mass spectrometry.

Authors:  Wolfgang Schaefer; Hans R Völger; Stefan Lorenz; Sabine Imhof-Jung; Jörg T Regula; Christian Klein; Michael Mølhøj
Journal:  MAbs       Date:  2015-10-23       Impact factor: 5.857

Review 2.  Advances in Antibody Design.

Authors:  Kathryn E Tiller; Peter M Tessier
Journal:  Annu Rev Biomed Eng       Date:  2015-08-14       Impact factor: 9.590

Review 3.  The development of therapeutic monoclonal antibodies: overview of the nonclinical safety assessment.

Authors:  Janice A Lansita; Barbara Mounho-Zamora
Journal:  Curr Pain Headache Rep       Date:  2015

4.  Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

Authors:  Xiufeng Wu; Arlene J Sereno; Flora Huang; Steven M Lewis; Ricky L Lieu; Caroline Weldon; Carina Torres; Cody Fine; Micheal A Batt; Jonathan R Fitchett; Andrew L Glasebrook; Brian Kuhlman; Stephen J Demarest
Journal:  MAbs       Date:  2015       Impact factor: 5.857

Review 5.  Considerations for the Design of Antibody-Based Therapeutics.

Authors:  Dennis R Goulet; William M Atkins
Journal:  J Pharm Sci       Date:  2019-06-04       Impact factor: 3.534

6.  Purification of common light chain IgG-like bispecific antibodies using highly linear pH gradients.

Authors:  Beth Sharkey; Sarat Pudi; Ian Wallace Moyer; Lihui Zhong; Bianka Prinz; Hemanta Baruah; Heather Lynaugh; Sampath Kumar; K Dane Wittrup; Juergen H Nett
Journal:  MAbs       Date:  2016-12-12       Impact factor: 5.857

7.  Fabs-in-tandem immunoglobulin is a novel and versatile bispecific design for engaging multiple therapeutic targets.

Authors:  Shiyong Gong; Fang Ren; Danqing Wu; Xuan Wu; Chengbin Wu
Journal:  MAbs       Date:  2017-07-10       Impact factor: 5.857

8.  Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.

Authors:  K J Froning; A Leaver-Fay; X Wu; S Phan; L Gao; F Huang; A Pustilnik; M Bacica; K Houlihan; Q Chai; J R Fitchett; J Hendle; B Kuhlman; S J Demarest
Journal:  Protein Sci       Date:  2017-07-31       Impact factor: 6.725

9.  Balancing Selectivity and Efficacy of Bispecific Epidermal Growth Factor Receptor (EGFR) × c-MET Antibodies and Antibody-Drug Conjugates.

Authors:  Carolin Sellmann; Achim Doerner; Christine Knuehl; Nicolas Rasche; Vanita Sood; Simon Krah; Laura Rhiel; Annika Messemer; John Wesolowski; Mark Schuette; Stefan Becker; Lars Toleikis; Harald Kolmar; Bjoern Hock
Journal:  J Biol Chem       Date:  2016-09-30       Impact factor: 5.157

Review 10.  Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells.

Authors:  William R Strohl; Michael Naso
Journal:  Antibodies (Basel)       Date:  2019-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.